Hand-out
Press Releases
April 28, 2025
ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025
Oral presentation shows ADCT-242 targeting Claudin-6 was well-tolerated and demonstrated potent


